Myriad Genetics Inc, a biotechnology firm, has found two genes that may be responsible for genetic breast and ovarian cancer. The company hopes to patent the genes for which they completed the research to link to cancer. In August, a federal appeals court in Washington D.C. sustained their right to patent. On November 30th, the U.S. Supreme Court agreed to hear their case, and rule in what will surely set precedent for genetically related cases in the future. Earlier this year, the same court voted to not to allow the right to patenting human genes, it remains to be seen if the appeal will find a different ruling.